Discrepancies between Protease Inhibitor Concentrations and Viral Load in Reservoirs and Sanctuary Sites in Human Immunodeficiency Virus-Infected Patients
Open Access
- 1 January 2003
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (1) , 238-243
- https://doi.org/10.1128/aac.47.1.238-243.2003
Abstract
The variable penetration of antiretroviral drugs into sanctuary sites may contribute to the differential evolution of human immunodeficiency virus (HIV) and the emergence of drug resistance. We evaluated the penetration of indinavir, nelfinavir, and lopinavir-ritonavir (lopinavir/r) in the central nervous system, genital tract, and lymphoid tissue and assessed the correlation with residual viral replication. Plasma, cerebrospinal fluid (CSF), semen, and lymph node biopsy samples were collected from 41 HIV-infected patients on stable highly active antiretroviral therapy regimens to determine drug concentrations and HIV RNA levels. When HIV RNA was detectable, sequencing of the reverse transcriptase and protease genes was performed. Ratios of the concentration in semen/concentration in plasma were 1.9 for indinavir, 0.08 for nelfinavir, and 0.07 for lopinavir. Only indinavir was detectable in CSF, with a concentration in CSF/concentration in plasma ratio of 0.17. Differential penetration into lymphoid tissue was observed, with concentration in lymph node tissue/concentration in plasma ratios of 2.07, 0.58, and 0.21 for indinavir, nelfinavir, and lopinavir, respectively. HIV RNA levels were <50 copies/ml in all CSF samples of patients in whom HIV RNA was not detectable in plasma. HIV RNA was detectable in the semen of three patients (two patients receiving nelfinavir and one patient receiving lopinavir/r), and its detection was associated with multiple resistance mutations, while the viral load in plasma was undetectable. HIV RNA was detectable in all lymph node tissue samples. Differential drug penetration was observed among the three protease inhibitors in the sanctuary sites, but there was no correlation between drug levels and HIV RNA levels, suggesting that multiple factors are involved in the persistence of viral reservoirs. Further studies are required to clarify the role and clinical relevance of drug penetration in sanctuaries in terms of long-term efficacy and drug resistance.Keywords
This publication has 33 references indexed in Scilit:
- Residual Human Immunodeficiency Virus (HIV) Type 1 RNA and DNA in Lymph Nodes and HIV RNA in Genital Secretions and in Cerebrospinal Fluid after Suppression of Viremia for 2 YearsThe Journal of Infectious Diseases, 2001
- Selection of Drug‐Resistant Variants in the Female Genital Tract of Human Immunodeficiency Virus Type 1–Infected Women Receiving Antiretroviral TherapyThe Journal of Infectious Diseases, 2000
- Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic populationAIDS, 2000
- Nucleoside Analogues Achieve High Concentrations in Seminal Plasma: Relationship between Drug Concentration and Virus BurdenThe Journal of Infectious Diseases, 1999
- Persistence of Human Immunodeficiency Virus in Semen After Adding Indinavir to Combination Antiretroviral TherapyClinical Infectious Diseases, 1999
- Plasma and Cerebrospinal Fluid Saquinavir Concentrations in Patients Receiving Combination Antiretroviral TherapyClinical Infectious Diseases, 1999
- Resistance of HIV-1 to antiretroviral agents in blood and seminal plasmaAIDS, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Quantification of latent tissue reservoirs and total body viral load in HIV-1 infectionNature, 1997
- Detection of Low HIV-1 RNA Levels in PlasmaJAIDS Journal of Acquired Immune Deficiency Syndromes, 1997